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Abstract: Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic accumulation of lipids.
Antisteatotic effects of cerium oxide nanoparticles (CeO2NPs) have recently been shown in animal
models of liver disease. However, it is unclear whether the activity of CeO2NPs is related solely to
the decrease in oxidative stress or, in addition, they directly decrease liver fatty acid accumulation.
To address this question, in this work, we used an in vitro model of hepatocellular steatosis, exposing
HepG2 cells to oleic and palmitic acid. Cell uptake of CeO2NPs and their effect on oxidative stress
and viability of hepatic cells cultured with H2O2 were also evaluated. Results show that CeO2NPs
were uptaken by HepG2 cells and reduced oxidative stress and improved cell viability. Treatment
with oleic and palmitic acid increased lipogenesis and the content of different fatty acids. CeO2NPs
reduced palmitic and stearic acid and most fatty acids consisting of more than 18 carbon atoms. These
effects were associated with significant changes in elongase and desaturase activity. In conclusion,
CeO2NPs directly protected HepG2 cells from cell injury in oxidative stress conditions and reduced
fatty acid content in steatotic conditions by inducing specific changes in fatty acid metabolism, thus
showing potential in the treatment of NAFLD.
Keywords: nonalcoholic fatty liver disease; steatosis; liver; cerium oxide nanoparticles;
oxidative stress
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic lipid accumulation (steatosis),
mainly in the form of triglycerides, and covers a wide spectrum of liver disease that ranges from simple
hepatic steatosis (nonalcoholic fatty liver, NAFL) to nonalcoholic steatohepatitis (NASH), the last being
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characterized by the appearance of inflammation and a higher risk of progression to more advanced
forms including fibrosis, cirrhosis and hepatocellular carcinoma (HCC) [1].
Oxidative stress plays a role in the molecular mechanisms behind the progression of NAFLD. In this
regard, the pathogenesis of NAFLD may be explained by a multiple-hit hypothesis [2]. In the context
of excess energy, fatty acids (FAs) are esterified into triacylglycerides and stored in lipid droplets in the
liver. The multiple-hit hypothesis considers multiple insults, including insulin resistance, adipokines,
nutritional factors or gut microbiota that act together on genetically predisposed subjects in the
development and progression of the disease [2,3]. These insults are associated with increased oxidative
stress, proinflammatory cytokines and adipocytokines, leading to hepatocyte injury, inflammation and
fibrosis [4,5]. The hepatic accumulation of free FA, lipid peroxidation products (reactive aldehydes
and oxysterols) and reactive oxygen species (ROS) contribute to the development and progression
of NAFLD from simple steatosis to NASH by impairing mitochondrial function, energy balance and
biogenesis adaptation to chronic injury [6,7].
The current treatment of NAFLD consists of diet and lifestyle interventions, such as healthy eating
habits and physical activity, to achieve weight loss and the control of its associated cardio-metabolic
risk factors [8–10]. However, reinforcement of these interventions by pharmacological therapies would
be useful in the management of patients. Unfortunately, effective treatment options for NAFLD
remain limited [1]. At present, there are no pharmacological treatments licensed for the reduction of
liver steatosis, and the American and European guidelines for the management of NAFLD patients
are only supportive of the use of two drugs: pioglitazone in patients with NASH with or without
diabetes mellitus, and vitamin E, a recognized antioxidant, in nondiabetic patients with NASH [9,10].
The identification of strategies directed to halt NAFLD progression are, therefore, an urgent need.
In recent years, the antioxidant properties of cerium oxide nanoparticles (CeO2NPs) have been
widely described in the literature [11–16]. CeO2NPs, which display minimal toxicity to normal tissues
and provide cellular protection from various forms of ROS and irradiation [17], have emerged as
a powerful antioxidant therapeutic tool in the prevention and treatment of oxidative-stress-related
diseases. The interest in CeO2NPs include their natural advantages over other antioxidants since
CeO2NPs participate catalytically in redox cycles, which mean that they are not consumed during
reaction, and thus, they can be used at low doses. Their oxygen storage capacity has proven useful
in scavenging free radicals as soon as they are generated in situations of metabolic imbalance [12].
In this context, it has been shown that CeO2NPs exhibit superoxide dismutase [18], catalase [19] and
peroxidase [20] mimetic activities. Thus, CeO2NPs have been postulated as a possible treatment
for pathologies associated with chronic oxidative stress and inflammation such as cancer, cardiac
disease and neurodegenerative disease, among others [21–25]. Interestingly, after their administration,
CeO2NPs are accumulated mainly in the liver and for long periods of time [26,27]. Recent studies carried
out in our laboratory show that CeO2NPs decrease portal hypertension, liver inflammatory response and
hepatic steatosis in a rat model of liver fibrosis induced by CCl4 [27]. Additionally, oral administration
of CeO2NPs to a NAFLD rat model associated with neonatal monosodium-glutamate-induced obesity
has been reported to decrease body weight and liver steatosis [28]. However, it is unknown whether
this antisteatotic effect is due to a direct effect of CeO2NPs in the liver. In the current study, we used
an in vitro model system of cultured human hepatic cells (HepG2) to test the hypothesis of whether
CeO2NPs can directly reduce FA accumulation in the absence of other stimuli.
2. Materials and Methods
2.1. Synthesis and Characterization of CeO2NPs
2.1.1. Synthesis
CeO2NPs of 4 nm of mean diameter were synthesized in aqueous media by the chemical
precipitation of Cerium (III) Nitrate Hexahydrate (Ce(NO3)3) under basic conditions. Briefly, 10 mM
of Cerium (III) Nitrate Hexahydrate was dissolved in 97 mL of Milli-Q H2O at room temperature.
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The solution was left under stirring for about 30 min. To this, 3 mL of tetramethylammonium hydroxide
(TMAOH) (1.0 ± 0.02 M in H2O) was added under stirring (final TMAOH concentration of 30 mM),
and the mixture was left under stirring overnight. Afterward, nanoparticles (NPs) were purified by
centrifugation (20,000 g, 10 min) and resuspended in an aqueous solution of 1 mM TMAOH. In this
synthesis, the conversion of initial cerium precursor to CeO2NPs is nearly complete, as determined by
UV-VIS spectroscopy and inductively coupled plasma mass spectrometry (ICP-MS).
2.1.2. Albumin Conjugation
Electrostatically stabilized CeO2NPs have a strong tendency to aggregate at physiological pH,
which can result in deleterious immune responses [29]. To avoid this, Human Serum Albumin (HSA)
was conjugated to the CeO2NPs surface prior to their use. Albumin was added at 100-fold the amount
needed to cover the surface of CeO2NPs to ensure complete albumin corona formation.
2.1.3. Characterization
The NPs’ size was determined using high-resolution transmission electron microscopy (HR-TEM)
with a microscope JEOL JEM 2010F at 200 kV (Tokyo, Japan), and further image analysis using the
Image J free software (National Institutes of Health, Bethesda, MD, USA). The surface charge of the
NPs was characterized in a Z-sizer (Malvern, Worcestershire, UK). The crystal structure was analyzed
by X-ray powder diffraction (XRD) (Xpert Pannalytical, MA, USA), and the light interaction by UV-VIS
spectroscopy (Shimadzu, Kyoto, Japan).
2.2. Cell Culture
HepG2 cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA).
This immortalized human hepatocellular stable cell line can be repeatedly frozen, thawed and
propagated. HepG2 cells were seeded into either 96-well culture plates for cell bioavailability analysis,
24-well culture plates for ROS measurements, six-well culture plates for steatosis induction and
nanoparticles cell uptake evaluation or 75 cm2 flasks for measurements of oxysterols. After seeding,
cells were grown to confluence in Dulbecco’s Modified Eagle Medium (DMEM), supplemented
with 10% fetal bovine serum (FBS), 50 U/mL penicillin and 50 µg/mL streptomycin, in a humidified
atmosphere of 5% CO2 at 37 ◦C. Thereafter, the cells were switched to serum-free DMEM for 16 h.
For cell stimulation and treatment, old medium was removed and replaced with medium, medium
containing 1.5 mM H2O2 (Sigma-Aldrich, St. Louis, MO, USA) or medium containing 1.5 mM H2O2
and CeO2NPs. Cells were incubated for the indicated time points and then harvested for biochemical
or molecular assays. All experiments were repeated at least three times.
2.3. Internalization of CeO2NPs in HepG2 Cells
The uptake of CeO2NPs by the cell cultures was assessed using bright-field and dark-field TEM
images. HepG2 cells were seeded (1.5x106 cells/well) in six-well plates and incubated with or without
CeO2NPs (10 µg/mL) for 24 h. Thereafter, cells were fixed in a 0.1 M phosphate buffer containing 2.5%
glutaraldehyde and 2% paraformaldehyde. Cells were embedded in Spur’s resin and thin sections
(50–55 nm) were cut and placed on copper grids and then stained with uranyl acetate and lead citrate.
After staining, the sections were examined using a low-electron-power microscope to increase contrast
in a JEOL-1010 TEM (JEOL, Tokyo, Japan) operated at 80 kV and equipped with a BioScan camera
(Gatan, CA, USA).
2.4. Cell Viability Analysis
Cell viability was assessed using the MTS (3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) technique (CellTiter 96; Promega,
Madison, WI, USA) according to the manufacturer’s instructions. In brief, cells were seeded
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(1 × 105 cells/well) in 96-well plates and, after overnight starvation, cells were treated with medium,
H2O2 (1.5 mM) or H2O2 and CeO2NPs (10 µg/mL) for 90 min at 37 ◦C. Then, cells were washed
twice with Hank’s Balanced Salt Solution (HBSS) and CellTiter reagent was added to each well.
After incubation for 3 h at 37 ◦C to allow cells to bioreduce MTS into formazan, the absorbance of
formazan, measured at 490 nm (SpectraMax 340, Molecular Devices, Sunnyvale, CA), is directly
proportional to the number of living cells in culture.
2.5. Reactive Oxygen Species Measurement
Fluorescence spectrophotometry was used to measure ROS, with 2’,7’-DCF-DA
(2’,7’-dichlorofluorescein diacetate) as the probe (Sigma-Aldrich, St. Louis, MO, USA). DCF-DA
readily diffuses through the membrane and is enzymatically hydrolyzed by intracellular esterases to
the nonfluorescent DCFH (2’,7’-dichlorodihydrofluorescein), which can then be rapidly oxidized to
fluorescent DCF in the presence of ROS. HepG2 cells were seeded in 24-well plates and, after overnight
starvation, cells were incubated alone or with H2O2 (1.5 mM) in the presence of CeO2NPs (1 µg/mL) or
medium for 90 min. Thereafter, cells were washed with HBSS and incubated with 10-µM DCF-DA
in Hanks Balanced Salt Solution for 40 min at 37 ◦C in the dark. The supernatant was collected to
measure the production of ROS, and the intensity of DCF fluorescence was immediately read in a
fluorescence spectrophotometer (FLUOstar OPTIMA; BMG LABTECH, Ortenberg, Germany) at 485 nm
for excitation and at 520 nm for emission.
2.6. Oxysterols Measurements
Cells were seeded in 75-cm2 flasks and, after overnight starvation, incubated with medium,
H2O2 (1.5 mM) or H2O2 and CeO2NPs (1.5 mM; 10 µg/mL) for 90 min. Afterward, cell pellets were
obtained by trypsinization and the oxysterol content was analyzed. Cholesterol, cholesterol d7,
7β-hydroxycholesterol, 7-ketocholesterol, 25-hydroxycholesterol and 5α-cholestane were purchased
from Steraloids (Newport, RI). Lipids were extracted from HepG2 cells with chloroform–methanol
(2:1vol/vol) in the presence of butylated hydroxytoluene (0.005%) as an antioxidant. 5α-cholestane and
cholesterol-d7 were added as internal standards. After centrifugation, the lower phase was evaporated
under a nitrogen stream and extracts were silylated with N,O-bis-(trimethylsilyl)-trifluoroacetamide
containing 1% trimethylchlorosilane (Sigma). Gas chromatography mass spectrometry (GC–MS)
analyses were performed on a Shimadzu GCMS QP2010 Ultra instrument (Kyoto, Japan). Sterols
were separated in a Sapines-5MS+ capillary column (30 m × 0.25 mm internal diameter × 0.25 µm
film thickness) from Teknokroma with helium as a carrier gas at a constant velocity of 50 cm/s.
The temperature program was programmed to begin at 50 ◦C and this temperature was maintained for
3 min. Then, it was elevated at a rate of 80 ◦C min−1 to 240 ◦C, before being increased at 2 ◦C min−1
to a temperature of 290 ◦C and finally, maintained for 2 min at 290 ◦C. The ion source and transfer
line temperatures were set to 270 ◦C and 280 ◦C, respectively. Mass detector was operated in selected
ion monitoring (SIM) mode and identification of the analytes was achieved by GC retention time
comparison with reference standards. No oxidation of d7-cholesterol to deuterated oxysterols was
observed during the analytical procedure.
2.7. Induction of Steatosis in HepG2 Cells with Oleic and Palmitic Acids
HepG2 cells were seeded (1.5 × 106 cells/well) in six-well plates and grown to confluence as
described above. After overnight starvation, the medium was changed to 10% FBS medium or 10%
FBS medium with 1.33 mM oleic acid (OA) and 0.67 mM palmitic acid (PA) with or without CeO2NPs
(10 µg/mL) for 24 h to induce the hepatosteatotic condition [30,31]. Three cell cultures were compared:
(i) cells incubated with 10% FBS medium, (ii) cells incubated with 10% FBS medium and OA+PA, (iii)
cells incubated with 10% FBS and OA+PA and CeO2NPs (10 µg/mL).
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2.8. Total FA Measurements
Lipids were extracted from HepG2 cells with chloroform–methanol (2:1 vol/vol) in the presence of
butylated hydroxytoluene (0.005%). C19:0 (Sigma Aldrich, Madrid, Spain) was used as an internal
standard. After homogenization, samples were placed on an orbital shaker for 20 min at room
temperature and centrifuged for 10 min at 10,000 rpm. The supernatant was mixed with 250 µL of
water, vortexed and centrifuged again for 10 min at 10,000 rpm. The lower organic phase was retrieved,
evaporated under a nitrogen stream and redissolved in a mixture of methanol:hexane (4:1, v/v). Acetyl
chloride was added and FA methyl ester (FAME) obtained by heating the samples at 100 ◦C for 1 h.
GC–MS analyses were performed on a Shimadzu GCMS QP2010 Ultra instrument (Kyoto, Japan).
Final extracts were injected into the gas chromatograph interfaced with a mass selective detector.
Chromatographic separation was achieved on a Sapines-5MS+ capillary column (30 m × 0.25-mm
internal diameter × 0.25-µm film thickness) from Teknokroma (Barcelona, Spain) with helium as a
carrier gas at a constant velocity of 50 cm/s. The temperature program was set to begin at 50 ◦C and this
temperature was maintained for 3 min. Then, it was elevated at a rate of 80 ◦C min−1 to 240 ◦C, before
being increased at 2 ◦C min−1 until 290 ◦C and finally, maintained for 2 min at 290 ◦C. The ion source
and transfer line temperatures were set to 270 ◦C and 280 ◦C, respectively. Mass detector was operated
in scan mode. Identification of the FAME in the sample extracts was achieved by mass spectrum and
GC retention time comparison with reference standards. The activities of FA elongases and desaturases
were estimated, assessing established product to precursor metabolic ratios for each reaction [32–34].
In addition, the lipogenic index was calculated as the ratio C16:0/C18:2n6c [35,36].
2.9. Statistical Analysis
Quantitative data were analyzed using GraphPad Prism 6 (GraphPad Software Inc.,
San Diego, CA, USA) and statistical analysis of the results was performed by an unpaired t-test.
Data is expressed as mean ± standard error of the mean (SEM) and considered significant at a p-level
of 0.05 or less. The study was performed according to the criteria of the Investigation and Ethics
Committee of the Hospital Clínic of Barcelona.
3. Results
3.1. Characterization of CeO2NPs
A description of the characterization of the CeO2NPs used in this study has been published
previously [27]. Briefly, the measured Z-Potential of CeO2NPs was +40 mV at the final synthesis pH
(pH = 6). The X-ray diffraction pattern showed pure CeO2NPs with the typical peak broadening
characteristic of nanosized particles. In this synthesis, CeO2NPs obtained are monodisperse with an
average of 4±1 nm size, as determined by TEM. In these conditions, the high surface energy of the
NPs makes their electrical double layer unable to keep them apart and small agglomerates are formed.
To avoid that, their immediate albuminization as they are formed, once the extreme initial pH of the
solution is reduced (from pH 12 to pH 6), is key. HSA conjugation on the surface of the CeO2NPs has
been characterized by the increase in DLS and modification of the Z-Potential (from +40 mV of NPs as
synthesized to −14 mV, which is the average Z-Potential value of the HSA (Figure 1).
3.2. Cellular Uptake of CeO2NPs
Transmission electron microscopy was used to evaluate the association between HepG2 cells
and incubation with CeO2NPs (10 µg/mL) for 24 h. TEM images revealed the presence of CeO2NPs
inside the cells, mainly in membrane-bound compartments and to a lesser extent, free in the cytoplasm
(Figure 2). The presence of CeO2NPs is revealed in the dark-field images since the high contrast of
cerium oxide (CeO2) crystals allowed them to be easily distinguished (as bright spots) from other
cellular structures. The confinement of CeO2NPs mainly in vacuoles or endosome-like organelles
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suggested their presence in secretory compartments. These structures were not observed in the TEM
images obtained from controls cells incubated without CeO2NPs.Biomolecules 2019, 9, x FOR PEER REVIEW 6 of 17 
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time shows the stability in the physiological media of the NPs used; (c) Dynamic light scattering 
(DLS) of CeO2NPs as synthesized, HSA, and CeO2NPs@HSA. While the spectrum of CeO2NPs shows 
a large presence of agglomerated NPs, the similar spectra of HSA and CeO2NPs@HSA rules out the 
presence of CeO2 aggregates. Note, that all samples have been purified before measurement. 
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easily distinguished. MBC indicates a membrane-bound compartment, N the nucleus and C the 
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To evaluate cellular CeO2NPs protection from H2O2-induced cytotoxicity in human hepatic 
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Figure 1. CeO2NPs characterization. (a) Transmission electron microscopy (TEM) and high-resolution
transmission electron microscopy (HR-TEM) (inset) showing the as-synthesized cerium oxide (CeO2)
nanocrystals of 4±1 nm; (b) UV-VIS spectroscopy of CeO2NPs after conjugation to Human Serum
Albumin (HSA) (CeO2NPs@HSA) and the same nanoparticles (NPs) after 48 h in model physiological
media (DMEM + Fetal Bovine Serum at 10% v/v). The similar spectra through time shows the stability in
the physiological media of the NPs used; (c) Dynamic light scattering (DLS) of CeO2NPs as synthesized,
HSA, and CeO2NPs@HSA. While the spectrum of CeO2NPs shows a large presence of agglomerated
NPs, the similar spectra of HSA and CeO2NPs@HSA rules out the presence of CeO2 aggregates. Note,
that all samples have been purified before measurement.
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3.3. Effect of CeO2NPs in the Viability of HepG2 Incubated with H2O2
To evaluate cellular CeO2NPs protection from H2O2-induced cytotoxicity in human hepatic cells,
HepG2 cells were incubated with H2O2 and cellular viability was analyzed in the presence of CeO2NPs
or vehicle. Oxidative stress induced with a 1.5 mM H2O2 produced a reduction in cell viability of 14%
(control 100% ± 1.8% and H2O2 85.8% ± 1.1% viability (mean ± SEM); p < 0.0001). In these conditions,
CeO2NPs treatment improved cell viability, from 85.8% ± 1.1% in the H2O2 condition to 99.6% ± 1.8%
in cells exposed to H2O2 nd treated with NPs (p < 0.0001), indicating that CeO2NPs protect from the
oxidative-stress-associated cell death induced by H2O2 in HepG2 cells (Figure S1A).
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3.4. Effect of CeO2NPs in the ROS Production of HepG2 Incubated with H2O2
HepG2 cells incubated with H2O2 (1.5 mM) increased ROS production by 25% (control 100%± 3.9%
and H2O2 125.4% ± 3.3% (mean ± SEM); p < 0.0001), as determined by fluorescence spectrophotometry
using the oxidant-sensitive dye 2´,7´-DCF-DA. ROS production was significantly inhibited in the
presence of CeO2NPs (H2O2 125.4% ± 3.3% and H2O2 with CeO2NPs 109.8% ± 3.8% (mean ± SEM);
p = 0.006). These results indicate that CeO2NPs protect from the oxidative stress induced by H2O2 in
HepG2 cells (Figure S1B).
3.5. Effect of CeO2NPs in Cholesterol and Oxysterols Content of HepG2 Cells Treated with H2O2
Effects of CeO2NPs in the cellular content of cholesterol and cholesterol oxidation products were
evaluated in HepG2 cells treated with vehicle, HepG2 cells treated with H2O2 (1.5 mM) and HepG2
cells treated with H2O2 and CeO2NPs (1.5 mM, 10 µg/mL). Figure 3A shows a chromatogram of
cholesterol and cholesterol oxidation products obtained by GC–MS in HepG2 cells. Cholesterol content
was approximately 1000-fold higher than cholesterol oxidation products. The most abundant oxysterol
measured was 7-ketocholesterol, followed by 7β-hydroxycholesterol and 25-hydroxycholesterol.
No significant differences in cholesterol content were observed between cells treated with vehicle,
H2O2 or H2O2 and CeO2NPs. In contrast, cells treated with H2O2 presented a higher content of
7β-hydroxycholesterol. Treatment with CeO2NPs reduced the concentration of oxysterols, although
this decrease was not statistically significant (Figure 3B). Similar results were obtained when the ratio
of oxysterol/cholesterol was calculated.
Biomolecules 2019, 9, x FOR PEER REVIEW 7 of 17 
CeO2NPs or vehicle. Oxidative stress induced with a 1.5 mM H2O2 produced a reduction in cell 
viability of 14% (control 100% ± 1.8% and H2O2 85.8% ± 1.1% viability (mean ± SEM); p < 0.0001). In 
these conditions, CeO2NPs treatment improved cell viability, from 85.8% ± 1.1% in the H2O2 
condition to 99.6% ± 1.8% in cells exposed to H2O2 and treated with NPs (p < 0.0001), indicating that 
CeO2NPs protect from the oxidative-stress-associated cell death induced by H2O2 in HepG2 cells 
(Figure S1A). 
3.4. Effect of CeO2NPs in the ROS Production of HepG2 Incubated with H2O2.  
HepG2 cells incubated with H2O2 (1.5 mM) increased ROS production by 25% (control 100% ± 
3.9% and H2O2 125.4% ± 3.3% (mean ± SEM); p < 0.0001), as determined by fluorescence 
spectrophotometry using the oxidant-sensitive dye 2 ,´7 -´DCF-DA. ROS production was significantly 
inhibited in the presence of CeO2NPs (H2O2 125.4% ± 3.3% and H2O2 with CeO2NPs 109.8% ± 3.8% 
(mean ± SEM); p = 0.006). These results indicate that CeO2NPs protect from the oxidative stress 
induced by H2O2 in HepG2 cells (Figure S1B). 
3.5. Effect of CeO2NPs in Cholesterol and Oxysterols Content of HepG2 Cells Treated with H2O2.  
Effects of CeO2NPs in the cellular content of cholesterol and cholesterol oxidation products 
were evaluated in HepG2 cells treated with vehicle, HepG2 cells treated with H2O2 (1.5 mM) and 
HepG2 cells treated with H2O2 and CeO2NPs (1.5 mM, 10 µg/mL). Figure 3A shows a chromatogram 
of cholesterol and cholesterol oxidation products obtained by GC–MS in HepG2 cells. Cholesterol 
content was approximately 1000-fold higher than cholesterol oxidation products. The most 
abundant oxysterol measured was 7-ketocholesterol, followed by 7β-hydroxycholesterol and 
25-hydroxycholesterol. No significant differences in cholesterol content were observed between cells 
treated with vehicle, H2O2 or H2O2 and CeO2NPs. In contrast, cells treated with H2O2 presented a 
higher content of 7β-hydroxycholesterol. Treatment with CeO2NPs reduced the concentration of 
oxysterols, although this decrease was not statistically significant (Figure 3B). Similar results were 
obtained when the ratio of oxysterol/cholesterol was calculated. 
 
Figure 3. (a) Gas chromatography mass spectrometry chromatograms of cholesterol and its oxidation 
products in HepG2 cells; (b) oxysterols content in HepG2 cells treated with vehicle, H2O2 (1.5 mM) 
and H2O2 and CeO2NPs (1.5 mM; 10 µg/mL). * p < 0.05 compared with control. 
3.6. Effects of CeO2NPs in Total FA Content of HepG2 Cells Treated with Oleic and Palmitic Acid. 
i re 3. (a) Gas chro atography ass spectro etry chro atogra s of cholesterol a its oxi atio
products in ep 2 cells; (b) oxysterols content in HepG2 cells treated with vehicle, H2O2 (1.5 mM) and
H2O2 and CeO2NPs (1.5 mM; 10 µg/mL). * p < 0.05 compared with control.
3.6. Effects of CeO2NPs in Total FA Content of HepG2 Cells Treated with Oleic and Palmitic Acid
Oleic and palmitic acid treatment of HepG2 was used as an in vitro model to investigate the
effect of CeO2NPs in steatosis. HepG2 cells were exposed to 1.33 mM oleic acid (OA) and 0.67 mM
palmitic acid (PA) for 24 h and intracellular accumulation of total FAs was measured by GC–MS.
A chromatogram showing FAs in HepG2 cells is presented in Figure 4A. Consistent with the induction
of the steatosis, total FAs content in HepG2 cells was increased in cells exposed to OA and PA in
comparison to those exposed to vehicle (Figure 4B). Treatment with CeO2NPs of cells exposed to OA
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and PA produced a significant reduction of total saturated FAs (Figure 4C), while the total amount of
unsaturated FAs was not significantly reduced (Figure 4D).
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Content of total fatty acids (b), saturated fatty acids (c) and unsaturated fatty acids (d) in HepG2 cells
exposed to vehicle (control), oleic acid:palmitic acid (OA:PA) (1.33:0.67 mM) and OA:PA with CeO2NPs
(10 µg/mL). * p < 0.05 compared with control; # p < 0.05 compared with OA:PA.
3.7. CeO2NPs Induce Specific Changes in the FA Metabolism of Steatotic HepG2 Cells
Analysis of the individual FA species showed that, compared to normal cells, HepG2 cells exposed
to OA and PA presented significant elevations in the intracellular content of different FA. As represented
in Figure S2 and Table S1 (Supplementary Material), OA and PA incubation increased the cell content of
C16:0, C18:0, C18:1n9c, C20:0, C20:1n9, C20:2n6, C20:5n3, C22:6n3 and C24:1n9. Interestingly, CeO2NPs
treatment of cells exposed to OA and PA decreased the cell content of most of these FA. Thus, CeO2NPs
treatment resulted in a 26% and 35% significant reduction of the highly abundant saturated FAs C16:0
and C18:0, respectively, and also, significantly decreased the content of very-long-chain saturated
FA C23:0 by 58% (Figure 5). Regarding unsaturated FA, CeO2NPs reduced the content of most FAs
consisting of more than 18 carbon atoms, such as C20:1n9, C20:2n6, C20:3n6, C20:4n6, C20:5n3, C22:6n3
and C24:1n9 (Figure 6). In contrast, C18:3n3 and C18:3n6 content increased 44% and 10%, respectively,
in cells treated with CeO2NPs.
In order to determine the mechanism of CeO2NPs antisteatotic effect, metabolic pathways of
FAs were investigated. The activities of the main FA elongases (elongation of very-long-chain fatty
acids 5 and 6 (ELOVL5 and ELOVL6)), and desaturases (steroyl-CoA desaturase 1 (SCD1) and fatty
acid desaturase 1 and 2 (FADS1 and FADS2)), were estimated by measuring the ratios between their
products and substrates (Figure 7). Results showed that steatotic HepG2 cells presented an elevation
of the lipogenic index C16:0/C18:2n6, which was associated with an activation of the elongase ELOVL5
and an inhibition of the desaturase SCD1 activities. CeO2NPs treatment reduced the lipogenic index
and reversed the changes in the elongase and desaturase activities induced by OA and PA. In addition,
steatosis-induced elongation and desaturation towards the n-3 and n-6 pathway were normalized after
steatotic cells were treated with CeO2NPs. Scheme 1 shows specific changes in FA metabolism induced
by CeO2NPs in steatotic cells.
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Figure 7. Fatty acid elongase and desaturase activities and lipogenic index in control cells, cells
incubated with OA:PA (1.33:0.67 mM) and cells incubated with OA:P treat d with CeO2NP ( µg/mL).
C20:2n6/C18:2n6c (ELOVL5) (a); C18:0/C16:0 (ELOVL6) (b); C16:1/C16:0 (SCD1-C16:0) (c); C18:1n9c/C18:0
(SCD1-C18:0) (d); C20:4n6/C20:3n6 (FADS1) (e); C18:3n3/C18:2n6c (FADS2) (f); C20:4n6/C18:2n6c
(ELOVL5 + FADS1 + FADS2 n-6 pathway) (g); C20:5n3/C18:3n3 (ELOVL5 + FADS1 n-3 pathway) (h);
C16:0/C18:2n6c (lipogenic index) (i). * p < 0.05 compared with control; # p < 0.05 compared with OA:PA.Biomolecules 2019, 9, x FOR PEER REVIEW 11 of 17 
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4. Discussion
The current study shows that CeO2NPs present protective cellular effects and reduce FA content
in cultured human hepatic cells (HepG2 cells) cultivated under characteristic conditions of NAFLD.
Specifically, cells were cultured under oxidative stress (H2O2 induced) or steatosis (OA:PA induced) in
order to evaluate if CeO2NPs presented a direct effect in these specific conditions. First, we evaluated
whether CeO2NPs were uptaken by HepG2 cells since, after intravenous administration of CeO2NPs
(3–20 nm), they have been observed to be located within hepatocytes of healthy mice [37] and rats
with advanced liver disease [27]. In agreement with these in vivo studies, TEM images obtained in
the current study revealed the uptake by HepG2 cells of CeO2NPs, which were confined in vacuoles
or endosome-like organelles. Similar observations have been reported when studying the uptake of
CeO2NPs by human hepatic cells C3A, in which confocal microscopy revealed a main perinuclear
location of nanoparticles that suggested their presence in late endocytic or secretory compartments [38].
Furthermore, internalization of CeO2NPs has been detected in human hepatic cells WRL-68 by flow
cytometry [39].
Increased hepatic oxidative stress is a main physiopathological characteristic of NAFLD [40,41].
Increased ROS generation triggers lipid peroxidation, release of inflammatory cytokines and cell
death. Patients with NASH display both an increase in ROS and nitrogen species production and a
lack of endogenous antioxidant defenses [40]. In this regard, we next evaluated whether CeO2NPs
could directly decrease cellular oxidative stress in hepatic cells cultured with hydrogen peroxide
(H2O2). CeO2NPs produced a reduction in H2O2-induced cellular oxidative stress, as indicated by the
decreased fluorescence of the oxidant-sensitive dye 2′,7′-DCF-DA. This reduction in oxidative stress in
CeO2NPs-treated cells was accompanied by an improvement in cellular viability measured by the MTS
assay. These results indicate that CeO2NPs directly protect human hepatic cells from oxidative stress
and the associated cellular injury. In agreement with this observation, Azari et al. [42] recently found
that pretreatment of HepG2 cells with CeO2NPs prevented oxidative and cellular damage caused by
acrylamide, a toxic chemical compound present in cooked foods.
Also related to enhanced ROS production in NAFLD is the increase of hepatic oxidized cholesterol
metabolites, which have been related to the progression of NAFLD [6,7]. Free cholesterol is susceptible
to enzymatic and non-enzymatic oxidation, leading to the formation of a number of cholesterol
oxidation products, including 25-hydroxycholesterol (enzymatic reaction) and 7β-hydroxycholesterol
and 7-ketocholesterol (non-enzymatic) [43]. Our findings indicate an increase in 7β-hydroxycholesterol,
7-ketocholesterol and 25-hydroxycholesterol when HepG2 cells were exposed to an oxidant stimulus
such as H2O2, suggesting that this is a suitable in vitro model for the study of cholesterol oxidation.
However, when cells were co-incubated with CeO2NPs, no significant reduction of oxysterols levels
was observed. Correction of oxysterols levels by cholesterol lead to a similar trend. Further studies are
necessary to ascertain the effect of CeO2NPs on oxysterol formation in liver cells.
NAFLD is usually characterized by the presence of hepatic liver steatosis [9,10]. There is evidence
derived from animal in vivo studies that CeO2NPs treatment may reduce liver steatosis in different
models of liver disease. Thus, in previous studies, our group first observed a reduction in liver steatosis
in a CCl4-induced model of liver fibrosis [27], and the same effect was reproduced in a methionine-
and choline-deficient diet model of steatohepatitis in rats [44]. Also, oral administration of CeO2NPs
to a NAFLD rat model associated with neonatal monosodium-glutamate-induced obesity has been
reported to decrease body weight and liver steatosis [28]. However, it is unknown whether these
antisteatotic effects are only related to a systemic and/or hemodynamic improvement, or if CeO2NPs
may also behave as antisteatotic agents per se. In addition, it is unknown whether similar antisteatotic
effects of CeO2NPs to those observed in rats may be found in the human liver. Interestingly, there is
evidence that CeO2NPs may interfere in the normal FA metabolism of human-derived hepatocytes
(HepG2 cells) [45,46], which represent the cell type in the liver that mainly accumulates FAs in NAFLD.
Therefore, in order to evaluate the ability of CeO2NPs to reduce FA content in human hepatic
cells, we next used an in vitro model of hepatocellular steatosis based on the administration of OA
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and PA (2:1 molar ratio) to HepG2 cells. Induction of steatosis in hepatic cells through incubation
with a mixture of OA (C18:1n9) and PA (C16:0) is an in vitro steatotic model widely used that is
useful to evaluate antisteatotic effects in hepatic cells since it mimics the liver steatosis of NAFLD in
patients [30,31,47,48]. OA, a monounsaturated FA, and PA, a saturated FA, are the most abundant
FAs present in liver triglycerides [49] and serum [50]. These FAs have individual cell effects: OA is
more steatogenic, while PA has a greater pro-apoptotic effect [31]. Exposure of HepG2 cells to a 2 mM
mixture of OA:PA with a ratio of 2:1 for 24 h provides the maximal lipid accumulation with minimal
cytotoxicity [30,31]. Gómez-Lechón et al. [30] found similar lipid accumulation in this in vitro model
of hepatocellular steatosis when compared to hepatocytes from a human steatotic liver.
Our data show that HepG2 cells incubated with OA and PA increased C16:0, C18:0, C18:1n9c,
C20:0, C20:1n9, C20:2n6, C20:5n3, C22:6n3 and C24:1n9. This is in agreement with a general induction
of FA content previously observed in this model [31] and in the liver of patients with NAFLD [32,51–53].
However, C18:3n3 and C18:3n6 levels were not increased. In agreement with this, other research
groups found low hepatic levels of C18:3n3 and C18:3n6 in animal models of NAFLD induced by a
high-fat diet and CCl4 [54] and a methionine- and choline-deficient diet [55], respectively.
PA (C16:0) increases the synthesis of C18:0 by elongation (ELOVL6), whereas OA (C18:1n9c) leads
to higher content of C20:1n9 and C24:1n9, according to the metabolic elongation pathway of n-9 fatty
acids. OA also promotes the formation of n-3 and n-6 long chain FAs through FADS2. Steatotic HepG2
cells presented decreased contents of C18:3n3 and C18:3n6, which may be associated with reduced
FADS2 activity. By contrast, C20:4n6, C20:5n3 and C22:6n3 were markedly increased, supporting an
induction of elongation and desaturation towards the n-3 and n-6 pathways. Overall, the increase in
the lipogenic index C16:0 / C18:2n6c on HepG2 cells exposed to OA and PA is also in agreement with
the induction of the steatotic metabolic process. Other indexes, such as C18:0/C16:0 (ELOVL6), which
is increased in this model, have been shown to relate to the degree of liver steatosis in patients with
NAFLD [51].
The antisteatotic effect of CeO2NPs was proven by reduction of the highly abundant saturated FA
C16:0 and C18:0 levels, together with a reduced content of most unsaturated FAs consisting of more
than 18 carbon atoms. A differential effect of CeO2NPs on C16:0 and C18:1n9 may be explained by the
fact that C16:0 is not readily esterified and, to avoid toxicity, is converted to unsaturated FAs (such as
C16:1n7 and C18:1n9) through elongation by EVOLV6 and desaturation by SCD1. Our data show that
CeO2NPs decreased ELOVL6 and increased SCD1 activities, which may explain why C16:1n7 and
C18:1n9 levels were not reduced after CeO2NPs treatment. Results suggest that CeO2NPs may induce
a more effective transformation of C16:0 to these unsaturated FAs to avoid toxicity.
The other significant FAs for which contents were reduced by CeO2NPs treatment were those
unsaturated FAs that consisted of more than 18 carbon atoms. The effect of CeO2NPs in the reduction of
these FAs was remarkable since many of them were completely normalized. This effect may be related
to the observed inhibition of elongation and desaturation towards the n-3 and n-6 pathway. Importantly,
CeO2NPs reduced the eicosanoid precursors C20:4n6, C20:5n3 and C22:6n3, which are involved in the
induction of inflammation and cell membrane integrity. However, provided that FAs consisting of
more than 18 carbon atoms are preferentially oxidized in peroxisomes rather than in mitochondria,
further research is necessary to evaluate whether CeO2NPs may also promote peroxisome FA oxidation.
In addition, C18:3n6 and C18:3n3 FA, which were not increased in steatotic HepG2 cells, exhibited
an increase in their levels when cells were treated with CeO2NPs, suggesting a CeO2NPs-mediated
induction of FADS2 activity. Finally, reduction of the lipogenic index by CeO2NPs supports an overall
antisteatotic effect.
One limitation of this study relates to the lack of evaluation of other factors that may also play a role
in the pathophysiology of NAFLD, together with oxidative stress and lipid dysregulations. A significant
example are the nuclear receptors, such as peroxisome proliferator-activated receptors (PPARs), liver
X receptors (LXR) and farnesoid X receptors (FXR). They have been involved in the natural history
of NAFLD, demonstrating that PPARs have one of the main roles in hepatic steatogenesis, LXR in
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hepatic inflammation and FXR in hepatic fibrogenesis [56]. Furthermore, TEM images showing the cell
uptake of CeO2NPs were only obtained in basal conditions and there could be some changes in the
localization of CeO2NPs under oxidative stress and/or steatotic conditions. Finally, the antisteatotic
effect of CeO2NPs was evaluated in an OA:PA mixture and differential effects on steatosis induced by
either OA alone or PA alone were not evaluated.
5. Conclusions
CeO2NPs directly protect human hepatic cells from cell injury in conditions of oxidative stress
and reduce FA content in steatotic conditions by inducing specific metabolic changes, suggesting that
these NPs have great potential in the treatment of NAFLD.
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